UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry

The American journal of surgical pathology, 2014-05, Vol.38 (5), p.627-637

2014

Volltextzugriff (PDF)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Journal for immunotherapy of cancer, 2019-03, Vol.7 (1), p.73-73, Article 73

2019

Volltextzugriff (PDF)

Author Correction: Towards individualized therapy for metastatic renal cell carcinoma

Nature reviews. Clinical oncology, 2019-10, Vol.16 (10), p.653-653

2019

Volltextzugriff (PDF)

Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial

BMJ Oncology, 2024-07, Vol.3 (1)

2024

Volltextzugriff (PDF)

Management of Kidney Cancer Relapse to Adjuvant Pembrolizumab: Early Insights and Questions for a Newly Emerging Space

European urology, 2024-09

2024

Volltextzugriff (PDF)

MP78-16 CORRELATION OF BAP1 AND PBRM1 MUTATIONAL STATUS AT TIME OF CYTOREDUCTIVE NEPHRECTOMY WITH SURVIVAL

The Journal of urology, 2016-04, Vol.195 (4), p.e1032-e1033

2016

Volltextzugriff (PDF)

MP71-10 CLINICAL FEATURES OF RECURRENT SOMATIC MUTATIONS IN CLEAR CELL RENAL CELL CARCINOMA: A LARGE COHORT

The Journal of urology, 2016-04, Vol.195 (4), p.e919-e919

2016

Volltextzugriff (PDF)

MP71-14 ANALYSIS OF THE MUTATIONAL LANDSCAPE OF SARCOMATOID CLEAR CELL RENAL CELL CARCINOMA COMPARED TO CONVENTIONAL CLEAR CELL RENAL CELL CARCINOMA

The Journal of urology, 2016-04, Vol.195 (4), p.e921-e921

2016

Volltextzugriff (PDF)

MP71-06 THE IMPACT OF TERT PROMOTER REGION MUTATIONS IN RENAL CELL CARCINOMA

The Journal of urology, 2016-04, Vol.195 (4), p.e917-e917

2016

Volltextzugriff (PDF)

MP71-07 GENETIC CONCORDANCE RATES OF MATCHED-PAIR RENAL CELL CARCINOMA SAMPLES PROVIDE EVIDENCE OF CLONAL EVOLUTION

The Journal of urology, 2016-04, Vol.195 (4), p.e917-e918

2016

Volltextzugriff (PDF)

MP71-11 GENOMIC LANSCAPE OF CLEAR CELL RENAL CELL CARCINOMA METASTASIS

The Journal of urology, 2016-04, Vol.195 (4), p.e919-e920

2016

Volltextzugriff (PDF)

MP23-09 INTEGRATED ANALYSIS OF METASTATIC DISEASE IN CLEAR CELL RENAL CELL CARCINOMA: A COLLABORATIVE TCGA ANALYSIS

The Journal of urology, 2014-04, Vol.191 (4), p.e246-e246

2014

Volltextzugriff (PDF)

Real world data on treatment of chromophobe renal cell carcinoma

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.409-409

2024

Volltextzugriff (PDF)

Hypoxia-inducible factor-2 alpha (HIF-2α) target activation and clinical outcomes in 942 patients with clear cell renal cell carcinoma

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.445-445

2024

Volltextzugriff (PDF)

MP28-02 CONSOLIDATIVE NEPHRECTOMY AFTER IMMUNOTHERAPY: OPERATIVE CHARACTERISTICS AND 90 DAY SURGICAL OUTCOMES

The Journal of urology, 2023-04, Vol.209 (Supplement 4)

2023

Volltextzugriff (PDF)

A phase I/II study of talazoparib and axitinib in patients with advanced clear cell renal cell carcinoma

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.4541-4541

2024

Volltextzugriff (PDF)

STARLITE 2: Phase 2 study of nivolumab plus 177 lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ( 177 Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS752-TPS752

2023

Volltextzugriff (PDF)

A robust, trial-agnostic gene signature for response to tyrosine kinase inhibition in ccRRCC

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4558-4558

2022

Volltextzugriff (PDF)

STARLITE 2: Phase 2 study of nivolumab plus 177 Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ( 177 Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4603-TPS4603

2022

Volltextzugriff (PDF)

Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4545-4545

2023

Volltextzugriff (PDF)

Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.TPS399-TPS399

2022

Volltextzugriff (PDF)

Reply by Authors

The Journal of urology, 2023-08, Vol.210 (2), p.279-280

2023

Volltextzugriff (PDF)

Impact of sarcomatoid features on treatment outcomes in metastatic clear cell renal cell carcinoma treated with first-line immunotherapy combinations

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.687-687

2023

Volltextzugriff (PDF)

1 – 25 von 157

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieThe Astrophysical Journal

ThemaAged

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(133)
Mit Volltextzugriff
(110)

Publikationsform

Sprache

Englisch
(143)
Deutsch
(14)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Author Correction: Towards individualized therapy for metastatic renal cell carcinoma

Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial

Clinical Outcomes and Targeted Genomic Analysis of Renal Cell Carcinoma Brain Metastases Treated with Stereotactic Radiosurgery

Management of Kidney Cancer Relapse to Adjuvant Pembrolizumab: Early Insights and Questions for a Newly Emerging Space

MP78-16 CORRELATION OF BAP1 AND PBRM1 MUTATIONAL STATUS AT TIME OF CYTOREDUCTIVE NEPHRECTOMY WITH SURVIVAL

MP71-10 CLINICAL FEATURES OF RECURRENT SOMATIC MUTATIONS IN CLEAR CELL RENAL CELL CARCINOMA: A LARGE COHORT

MP71-14 ANALYSIS OF THE MUTATIONAL LANDSCAPE OF SARCOMATOID CLEAR CELL RENAL CELL CARCINOMA COMPARED TO CONVENTIONAL CLEAR CELL RENAL CELL CARCINOMA

MP71-06 THE IMPACT OF TERT PROMOTER REGION MUTATIONS IN RENAL CELL CARCINOMA

MP71-07 GENETIC CONCORDANCE RATES OF MATCHED-PAIR RENAL CELL CARCINOMA SAMPLES PROVIDE EVIDENCE OF CLONAL EVOLUTION

MP71-11 GENOMIC LANSCAPE OF CLEAR CELL RENAL CELL CARCINOMA METASTASIS

Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures

MP23-09 INTEGRATED ANALYSIS OF METASTATIC DISEASE IN CLEAR CELL RENAL CELL CARCINOMA: A COLLABORATIVE TCGA ANALYSIS

Real world data on treatment of chromophobe renal cell carcinoma

Hypoxia-inducible factor-2 alpha (HIF-2α) target activation and clinical outcomes in 942 patients with clear cell renal cell carcinoma

MP28-02 CONSOLIDATIVE NEPHRECTOMY AFTER IMMUNOTHERAPY: OPERATIVE CHARACTERISTICS AND 90 DAY SURGICAL OUTCOMES

A phase I/II study of talazoparib and axitinib in patients with advanced clear cell renal cell carcinoma

STARLITE 2: Phase 2 study of nivolumab plus 177 lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ( 177 Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)

A robust, trial-agnostic gene signature for response to tyrosine kinase inhibition in ccRRCC

STARLITE 2: Phase 2 study of nivolumab plus 177 Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ( 177 Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)

Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma

Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC)

Reply by Authors

Impact of sarcomatoid features on treatment outcomes in metastatic clear cell renal cell carcinoma treated with first-line immunotherapy combinations

Aktive Filter

Suchergebnisse filtern